- Home
- GLTO vs APVO Comparison
GLTO vs APVO Comparison
Compare GLTO & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- APVO
- Stock Information
- Founded
- GLTO 2011
- APVO 2016
- Country
- GLTO Denmark
- APVO United States
- Employees
- GLTO N/A
- APVO N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- GLTO Health Care
- APVO Health Care
- Exchange
- GLTO Nasdaq
- APVO Nasdaq
- Market Cap
- GLTO 4.5M
- APVO 4.1M
- IPO Year
- GLTO 2020
- APVO N/A
- Fundamental
- Price
- GLTO $3.34
- APVO $1.98
- Analyst Decision
- GLTO Buy
- APVO Strong Buy
- Analyst Count
- GLTO 1
- APVO 1
- Target Price
- GLTO $10.00
- APVO $5,920.00
- AVG Volume (30 Days)
- GLTO 19.6K
- APVO 122.5K
- Earning Date
- GLTO 08-05-2025
- APVO 08-11-2025
- Dividend Yield
- GLTO N/A
- APVO N/A
- EPS Growth
- GLTO N/A
- APVO N/A
- EPS
- GLTO N/A
- APVO N/A
- Revenue
- GLTO N/A
- APVO N/A
- Revenue This Year
- GLTO N/A
- APVO N/A
- Revenue Next Year
- GLTO N/A
- APVO N/A
- P/E Ratio
- GLTO N/A
- APVO N/A
- Revenue Growth
- GLTO N/A
- APVO N/A
- 52 Week Low
- GLTO $2.01
- APVO $1.72
- 52 Week High
- GLTO $14.88
- APVO $381.10
- Technical
- Relative Strength Index (RSI)
- GLTO 45.88
- APVO 32.74
- Support Level
- GLTO $3.26
- APVO $1.87
- Resistance Level
- GLTO $3.48
- APVO $2.07
- Average True Range (ATR)
- GLTO 0.15
- APVO 0.18
- MACD
- GLTO -0.00
- APVO 0.04
- Stochastic Oscillator
- GLTO 51.52
- APVO 29.55
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.